IFM Investors Pty Ltd Has $25.67 Million Stock Holdings in Medtronic PLC $MDT

Posted by Francis Steltz on Jul 1st, 2026

IFM Investors Pty Ltd boosted its position in Medtronic PLC (NYSE:MDT – Free Report) by 4.3% in the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 296,199 shares of the medical technology company’s stock after buying an additional 12,117 shares during the period. IFM Investors Pty Ltd’s holdings in Medtronic were worth $25,666,000 at the end of the most recent quarter.

A number of other institutional investors have also added to or reduced their stakes in MDT. Brighton Jones LLC grew its position in Medtronic by 1,368.0% in the 4th quarter. Brighton Jones LLC now owns 39,989 shares of the medical technology company’s stock valued at $3,194,000 after purchasing an additional 37,265 shares during the period. Sivia Capital Partners LLC raised its holdings in Medtronic by 9.6% during the second quarter. Sivia Capital Partners LLC now owns 4,356 shares of the medical technology company’s stock worth $380,000 after buying an additional 381 shares during the last quarter. Jump Financial LLC bought a new position in shares of Medtronic in the second quarter valued at $299,000. Main Street Financial Solutions LLC lifted its stake in shares of Medtronic by 28.9% in the second quarter. Main Street Financial Solutions LLC now owns 14,356 shares of the medical technology company’s stock valued at $1,251,000 after buying an additional 3,218 shares in the last quarter. Finally, HUB Investment Partners LLC grew its holdings in shares of Medtronic by 21.3% during the second quarter. HUB Investment Partners LLC now owns 19,226 shares of the medical technology company’s stock valued at $1,676,000 after buying an additional 3,376 shares during the last quarter. 82.06% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling at Medtronic

In related news, EVP Harry Skip Kiil sold 4,189 shares of the stock in a transaction dated Monday, June 8th. The shares were sold at an average price of $80.44, for a total transaction of $336,963.16. Following the completion of the transaction, the executive vice president owned 37,227 shares in the company, valued at approximately $2,994,539.88. This represents a 10.11% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Company insiders own 0.26% of the company’s stock.

Key Stories Impacting Medtronic

Here are the key news stories impacting Medtronic this week:

Positive Sentiment: Some recent commentary argues Medtronic looks undervalued after its pullback, with bullish write-ups pointing to attractive valuation metrics and the company’s defensive healthcare profile as reasons the stock could offer upside from current levels. Article Title
Positive Sentiment: Medtronic has also been highlighted by some investors as a long-term holding, helped by the company’s recent FDA 510(k) clearance for its Nellcor pulse oximetry system, which could support its product pipeline and reinforce confidence in future innovation. Article Title
Positive Sentiment: Several bullish opinion pieces published over the past two days framed MDT as a potentially appealing buy for income and value-oriented investors, which may be helping offset some of the weakness from broader market sentiment. Article Title
Neutral Sentiment: Other coverage focused on how Medtronic compares with peers like Globus Medical, with analysts suggesting Medtronic may have less upside than faster-growing rivals. That comparison could weigh on sentiment, but it was more of a relative valuation discussion than a direct company-specific setback. Article Title
Negative Sentiment: Despite the bullish commentary, the stock has been trending lower recently, and a market recap noted MDT’s shares fell while the broader market gained, reinforcing concerns that investors may still be cautious about near-term growth and momentum. Article Title

Analyst Ratings Changes

Several equities research analysts have recently commented on MDT shares. Royal Bank Of Canada reissued an “outperform” rating and set a $118.00 target price on shares of Medtronic in a research report on Thursday, June 4th. UBS Group cut their price target on Medtronic from $90.00 to $85.00 and set a “neutral” rating for the company in a research note on Thursday, June 4th. Piper Sandler reissued a “neutral” rating and set a $85.00 price objective on shares of Medtronic in a report on Tuesday, June 16th. Weiss Ratings downgraded Medtronic from a “hold (c+)” rating to a “hold (c)” rating in a research note on Thursday, May 21st. Finally, Wells Fargo & Company dropped their target price on Medtronic from $114.00 to $102.00 and set an “overweight” rating on the stock in a report on Thursday, June 4th. Seventeen investment analysts have rated the stock with a Buy rating and ten have issued a Hold rating to the stock. According to MarketBeat, Medtronic presently has a consensus rating of “Moderate Buy” and an average target price of $99.00.

Get Our Latest Research Report on Medtronic

Medtronic Stock Down 3.3%

Medtronic stock opened at $78.25 on Wednesday. Medtronic PLC has a fifty-two week low of $73.31 and a fifty-two week high of $106.33. The company has a debt-to-equity ratio of 0.52, a quick ratio of 1.62 and a current ratio of 2.13. The firm’s 50-day simple moving average is $79.14 and its 200 day simple moving average is $89.37. The stock has a market cap of $100.17 billion, a PE ratio of 20.98, a price-to-earnings-growth ratio of 2.17 and a beta of 0.58.

Medtronic (NYSE:MDT – Get Free Report) last posted its quarterly earnings data on Wednesday, June 3rd. The medical technology company reported $1.55 EPS for the quarter, beating the consensus estimate of $1.54 by $0.01. Medtronic had a net margin of 13.20% and a return on equity of 14.51%. The firm had revenue of $9.81 billion during the quarter, compared to analyst estimates of $9.62 billion. During the same quarter last year, the business posted $1.62 EPS. The company’s revenue for the quarter was up 9.9% on a year-over-year basis. Medtronic has set its FY 2027 guidance at 5.900-6.000 EPS. Research analysts predict that Medtronic PLC will post 5.94 EPS for the current fiscal year.

Medtronic Increases Dividend

The firm also recently announced a quarterly dividend, which will be paid on Friday, July 17th. Stockholders of record on Friday, June 26th will be given a dividend of $0.72 per share. The ex-dividend date of this dividend is Friday, June 26th. This represents a $2.88 annualized dividend and a dividend yield of 3.7%. This is a boost from Medtronic’s previous quarterly dividend of $0.71. Medtronic’s payout ratio is 77.21%.

Medtronic Company Profile

(Free Report)

Medtronic plc is a global medical technology company that develops and manufactures a broad range of therapeutic devices and health care solutions. Headquartered legally in Ireland with principal operational offices in the United States, the company markets products to hospitals, physicians and health systems worldwide and has grown from its founding in 1949 into one of the largest medical-device manufacturers serving global health-care markets.

Medtronic’s offerings span several clinical areas, including cardiac rhythm and heart failure (pacemakers, implantable cardioverter‑defibrillators and related cardiac therapies), minimally invasive and surgical technologies (laparoscopic and advanced energy devices, visualization systems and surgical innovations), restorative therapies (spine and orthopedics, neuromodulation and neurovascular treatments) and diabetes management (insulin-delivery systems and glucose monitoring solutions).